Blood-based colorectal cancer screening test Epi proColon was more cost-effective than other alternative screening options, according to a company release about a study published in the Journal of the National Cancer Institute.
Researchers compared Epi proColon to computed tomographic colonography, PillCam and Cologuard. Researchers compared clinical effectiveness through five different scenarios, including a scenario that assumed the Epi proColon missed 12 percent of advanced adenomas and 18 percent of CRC cases.
What they found:
1. Annual screening with Epi proColon had an incremental cost-effectiveness ratio of $63,253 for every quality-adjusted life year gained.
2. CTC every five years had a ratio of $1,092 and annual Cologuard screening had a ratio of $214,974.
3. Researchers used a "willingness-to-pay" threshold of $100,000 for quality-adjusted life years gained.
4. Epi proColon was more cost-effective than Cologuard in all scenarios, but the authors concluded that the best test was the "one that gets done."